Fennec Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed on June 24, 2021, by Fennec Pharmaceuticals Inc., a British Columbia corporation with principal executive offices in Research Triangle Park, NC. The filing reports the entry into a material definitive agreement regarding a senior debt facility.
Key Financial Metrics and Transaction Details
The Company amended its existing senior debt facility with Bridge Bank (a division of Western Alliance Bank), increasing the total facility size from $18.0 million to $20.0 million. The facility consists of three term loans:
- Term Loan A: $5.0 million funded upon closing.
- Term Loan B: $7.5 million contingent on U.S. New Drug Application (NDA) approval of PEDMARK.
- Term Loan C: $7.5 million contingent on a revenue event in 2022.
On the closing date, the Company paid a good faith deposit of $42,600 and $8,400 to fund Term Loan A. The filing does not provide specific revenue, profit, cash flow, or margin figures for the period.
Material Changes and Covenants
The primary material change is the expansion of the debt facility to support commercial readiness and potential commercialization of PEDMARK. Key terms include:
- Interest Period: An interest-only period of 18 months, extendable to 24 months from the funding of Term Loan B if Term Loan C is funded and conditions are met.
- Prepayment: Voluntary prepayment is allowed in full but incurs a 1.00% premium on the outstanding principal.
- Liquidity Covenant: The Borrower must maintain unrestricted cash and cash equivalents equal to or greater than three times the monthly cash burn amount (calculated on a trailing six-month basis).
- Collateral: Secured by a first priority security interest in all assets excluding intellectual property, which is subject to a double negative pledge.
Outlook, Risks, and Contingencies
Management intends to use loan proceeds for working capital related to commercial readiness prior to NDA approval and for commercialization activities if PEDMARK is approved. The filing outlines several events of default that could accelerate repayment, including non-payment, failure to perform obligations, Material Adverse Events, seizure of assets, or insolvency proceedings.
Investor Verification Checklist
- Verify the status of the PEDMARK New Drug Application (NDA) to assess the likelihood of funding Term Loan B.
- Confirm the Company's current unrestricted cash balance against the covenant requirement of three times the monthly cash burn.
- Review the definition of "revenue event" in the full agreement to understand the trigger for Term Loan C.
- Monitor for any Material Adverse Events that could trigger an event of default.